Literature DB >> 6084217

A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors.

P Condon, L M Jampol, M D Farber, M Rabb, G Serjeant.   

Abstract

Follow-up of patients enrolled in a randomized prospective trial of feeder vessel photocoagulation for proliferative sickle cell retinopathy has shown that photocoagulation is effective in preventing vitreous hemorrhage and visual loss from vitreous hemorrhage. In addition, a reduction of visual loss from all causes in photocoagulated eyes approaches statistical significance. Analysis of control eyes shows that there are three independent risk factors for the occurrence of vitreous hemorrhage: (1) the presence of the SC genotype, (2) the presence of vitreous blood at the initial evaluation and, (3) the presence of greater than 60 degrees of perfused neovascularization.

Entities:  

Mesh:

Year:  1984        PMID: 6084217     DOI: 10.1016/s0161-6420(84)34121-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Ocular manifestations in egyptian children and young adults with sickle cell disease.

Authors:  Mona Kamal El-Ghamrawy; Hanan F El Behairy; Amal El Menshawy; Seham A Awad; Ahmed Ismail; Mohamed Salah Gabal
Journal:  Indian J Hematol Blood Transfus       Date:  2014-01-23       Impact factor: 0.900

2.  Outcome of iatrogenic choroidal neovascularisation in sickle cell disease.

Authors:  P D Fox; R W Acheson; G R Serjeant
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

3.  The ocular manifestations of sickle-cell disease: a prevalence and natural history study.

Authors:  J G Clarkson
Journal:  Trans Am Ophthalmol Soc       Date:  1992

Review 4.  Laser therapy for retinopathy in sickle cell disease.

Authors:  Kay Thi Myint; Soumendra Sahoo; Aung Win Thein; Soe Moe; Han Ni
Journal:  Cochrane Database Syst Rev       Date:  2015-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.